Farrell - I agree that there would be a jump in share price as a result of testing B that showed activity in pulmonary cells. However, I read the PR to indicate that clinical trials and testing of the pulmonary cells could happen concurrently. How that might be handled I don't know, but the fact that the PR mentions both the US and Europe seems to suggest that there may be interest in jumping directly to clinical trials in Europe since the discussion on additional testing is linked to a US laboratory. Do you read it the same way?